Genmab A/S ADR (GMAB)

$33.72 +0.07 (0.21%)
Market Cap 21.62B
Revenue (ttm) 3.12B
Net Income (ttm) 1.14B
EPS (ttm) N/A
PE Ratio 15.97
Forward PE 17.51
Profit Margin 36.44%
Debt to Equity Ratio 0.00
Volume 381,800
Avg Vol 1,858,126
Day's Range N/A - N/A
Shares Out 642.38M
Stochastic %K 94%
Beta 0.90
Analysts Strong Sell
Price Target $37.81

Company Profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 20 27 28
Address:
Carl Jacobsens Vej 30, Valby, Copenhagen, Denmark
StockConsultant
StockConsultant Dec. 23 at 2:06 PM
$GMAB Genmab stock, watch for a top of range breakout at https://stockconsultant.com/?GMAB
0 · Reply
savepig
savepig Dec. 22 at 11:34 PM
$GMAB Danish biotech: the bottom is in. BUY!
0 · Reply
LeRoyRektlord
LeRoyRektlord Dec. 22 at 10:23 PM
$CPRX $DLO $GMAB $CWAN
0 · Reply
SenefAS
SenefAS Dec. 19 at 7:23 AM
Today upgrade for Genmab $GMAB $GMAB.CO of Deutsche Bank for a buy with a new target of 2400 DK… Still partnership with Pfizer,Abbvie,BioNTech $PFE $ABBV $BNTX $NVS
0 · Reply
SenefAS
SenefAS Dec. 16 at 10:28 AM
Still in Genmab… Actually my favorite one… Sciences always win 😉 $GMAB $PFE
0 · Reply
benjamin_clark07
benjamin_clark07 Dec. 11 at 8:07 PM
$GMAB Mainz Biomed letting everyone get comfy thinking it’s dead at 1.05… then one day we wake up to a gap over 1.15 and Twitter screaming “what did I miss?” 📈
0 · Reply
johankirik
johankirik Dec. 11 at 7:13 PM
$GMAB Need a strong close today to continue bullish momentum.
0 · Reply
johankirik
johankirik Dec. 11 at 7:11 PM
$GMAB surprising these guys havent been acquired yet.
0 · Reply
Mergerbrief
Mergerbrief Dec. 11 at 1:07 PM
$MRUS / $GMAB – Tender Offer Expires MergerBrief.com For Full Schedule
0 · Reply
smartkarma
smartkarma Dec. 10 at 4:21 PM
$GMAB | Genmab: How Its Combined Pipeline, Royalties & M&A Strategy Could Potentially Unlock A SOLID Upside! "The Danish biotech giant is gearing up to acquire Merus N.V., a smaller Dutch peer, in a proposed $8 billion transaction announced on September 29, 2025." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/genmab-how-its-combined-pipeline-royalties-m-a-strategy-could-potentially-unlock-a-solid-upside
0 · Reply
Latest News on GMAB
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Dec 12, 2025, 1:36 AM EST - 13 days ago

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

MRUS

Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript

Dec 11, 2025, 4:22 PM EST - 14 days ago

Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

Dec 11, 2025, 2:00 AM EST - 14 days ago

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Dec 8, 2025, 4:30 PM EST - 17 days ago

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Dec 7, 2025, 7:50 AM EST - 18 days ago

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Dec 6, 2025, 9:30 AM EST - 19 days ago

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 4, 2025, 2:28 PM EST - 21 days ago

Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes

Dec 3, 2025, 3:03 PM EST - 22 days ago

Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Dec 1, 2025, 4:24 PM EST - 24 days ago

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Artisan International Small-Mid Fund Q3 2025 Performance Review

Nov 26, 2025, 8:05 AM EST - 4 weeks ago

Artisan International Small-Mid Fund Q3 2025 Performance Review

CIEN NICE ONC

Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami

Nov 24, 2025, 7:00 AM EST - 4 weeks ago

Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami

Genmab A/S (GMAB) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 22, 2025, 7:23 AM EST - 4 weeks ago

Genmab A/S (GMAB) Presents at Jefferies London Healthcare Conference 2025 Transcript

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Nov 20, 2025, 3:02 PM EST - 5 weeks ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Nov 19, 2025, 12:56 PM EST - 5 weeks ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility

Nov 18, 2025, 4:01 PM EST - 5 weeks ago

Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Nov 18, 2025, 2:58 PM EST - 5 weeks ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Nov 18, 2025, 11:30 AM EST - 5 weeks ago

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes

Nov 10, 2025, 10:51 AM EST - 6 weeks ago

Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes

Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility

Nov 10, 2025, 7:12 AM EST - 6 weeks ago

Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility

Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript

Nov 8, 2025, 6:46 AM EST - 6 weeks ago

Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript

Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London

Nov 5, 2025, 12:58 PM EST - 7 weeks ago

Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

Nov 3, 2025, 9:05 AM EST - 7 weeks ago

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

Oct 23, 2025, 12:43 PM EDT - 2 months ago

Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

MRUS

Why Is Genmab Stock Trading Lower On Monday?

Oct 20, 2025, 11:57 AM EDT - 2 months ago

Why Is Genmab Stock Trading Lower On Monday?

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Oct 18, 2025, 6:00 AM EDT - 2 months ago

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

Oct 14, 2025, 6:23 AM EDT - 2 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

Sep 30, 2025, 9:59 PM EDT - 3 months ago

MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

MRUS

Genmab A/S (GMAB) M&A Call Transcript

Sep 29, 2025, 5:47 PM EDT - 3 months ago

Genmab A/S (GMAB) M&A Call Transcript

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Sep 29, 2025, 10:15 AM EDT - 3 months ago

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

MRUS

This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.

Sep 29, 2025, 7:36 AM EDT - 3 months ago

This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.

MRUS

Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline

Sep 29, 2025, 3:23 AM EDT - 3 months ago

Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline

MRUS

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

Sep 29, 2025, 1:19 AM EDT - 3 months ago

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

MRUS

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Sep 29, 2025, 1:14 AM EDT - 3 months ago

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

MRUS

Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 25, 2025, 3:17 AM EDT - 3 months ago

Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Major Shareholder Announcement

Sep 23, 2025, 9:18 AM EDT - 3 months ago

Major Shareholder Announcement

Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy

Sep 14, 2025, 8:31 AM EDT - 3 months ago

Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy

Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff

Sep 12, 2025, 1:58 PM EDT - 3 months ago

Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff

Genmab: A Matter Of Time

Sep 12, 2025, 6:15 AM EDT - 3 months ago

Genmab: A Matter Of Time

Genmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 6:41 PM EDT - 3 months ago

Genmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

10 stocks to consider if you want alternatives to the expensive S&P 500

Sep 9, 2025, 2:39 PM EDT - 3 months ago

10 stocks to consider if you want alternatives to the expensive S&P 500

SPY AEG EFA NGG

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Sep 3, 2025, 8:30 AM EDT - 4 months ago

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 26, 2025, 9:31 AM EDT - 4 months ago

Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

Aug 26, 2025, 8:00 AM EDT - 4 months ago

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Aug 8, 2025, 1:23 PM EDT - 4 months ago

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

ABBV

Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:18 PM EDT - 5 months ago

Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript

Genmab Announces Financial Results for the First Half of 2025

Aug 7, 2025, 11:08 AM EDT - 5 months ago

Genmab Announces Financial Results for the First Half of 2025

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

Aug 7, 2025, 10:31 AM EDT - 5 months ago

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 5 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 5 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

Jul 16, 2025, 6:29 AM EDT - 5 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

StockConsultant
StockConsultant Dec. 23 at 2:06 PM
$GMAB Genmab stock, watch for a top of range breakout at https://stockconsultant.com/?GMAB
0 · Reply
savepig
savepig Dec. 22 at 11:34 PM
$GMAB Danish biotech: the bottom is in. BUY!
0 · Reply
LeRoyRektlord
LeRoyRektlord Dec. 22 at 10:23 PM
$CPRX $DLO $GMAB $CWAN
0 · Reply
SenefAS
SenefAS Dec. 19 at 7:23 AM
Today upgrade for Genmab $GMAB $GMAB.CO of Deutsche Bank for a buy with a new target of 2400 DK… Still partnership with Pfizer,Abbvie,BioNTech $PFE $ABBV $BNTX $NVS
0 · Reply
SenefAS
SenefAS Dec. 16 at 10:28 AM
Still in Genmab… Actually my favorite one… Sciences always win 😉 $GMAB $PFE
0 · Reply
benjamin_clark07
benjamin_clark07 Dec. 11 at 8:07 PM
$GMAB Mainz Biomed letting everyone get comfy thinking it’s dead at 1.05… then one day we wake up to a gap over 1.15 and Twitter screaming “what did I miss?” 📈
0 · Reply
johankirik
johankirik Dec. 11 at 7:13 PM
$GMAB Need a strong close today to continue bullish momentum.
0 · Reply
johankirik
johankirik Dec. 11 at 7:11 PM
$GMAB surprising these guys havent been acquired yet.
0 · Reply
Mergerbrief
Mergerbrief Dec. 11 at 1:07 PM
$MRUS / $GMAB – Tender Offer Expires MergerBrief.com For Full Schedule
0 · Reply
smartkarma
smartkarma Dec. 10 at 4:21 PM
$GMAB | Genmab: How Its Combined Pipeline, Royalties & M&A Strategy Could Potentially Unlock A SOLID Upside! "The Danish biotech giant is gearing up to acquire Merus N.V., a smaller Dutch peer, in a proposed $8 billion transaction announced on September 29, 2025." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/genmab-how-its-combined-pipeline-royalties-m-a-strategy-could-potentially-unlock-a-solid-upside
0 · Reply
Hottehueh
Hottehueh Dec. 7 at 5:47 PM
$GMAB
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 7 at 4:36 PM
The attached graph compares $NUVB analyst consensus revenue estimates to the same for $MRUS as of the day MRUS was acquired by $GMAB for an enterprise value of roughly $7.3B. We also noted MRUS management/BOD revenue projections were 2X higher than analysts (which may be absurd for all we know). Analysts forecast NUVB to generate roughly 80% of the revenues analysts project MRUS to generate at peak. NUVB market cap is roughly 40% of MRUS's EV. NUVB also has roughly $500MM cash at 9/30/2025. This is not investment advice as NUVB may be wildly overhyped for all we know. NUVB analyst revenue projections may also be fiction. We are merely sharing comparative data points. It is quite possible NUVB loses 70-80% of its market cap over the next 6 months. If NUVB is smart & pro-shareholder, it will seek an exit while its valuation has already soared. $XBI $IBB
3 · Reply
AlertsAndNews
AlertsAndNews Dec. 6 at 9:43 PM
$GMAB GMAB Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) "New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FL Latest EPCORE DLBCL-3 trial results show encouraging overall response and complete response rates for epcoritamab monotherapy in newly-diagnosed, elderly patients with DLBCL"
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 3 at 10:24 AM
$GMAB Current Stock Price: $31.70 Contracts to trade: $30 GMAB Dec 19 2025 Call Entry: $1.80 Exit: $2.46 ROI: 37% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Moonz8
Moonz8 Dec. 1 at 9:21 PM
$GMAB https://www.tradingview.com/news/reuters.com,2025-11-20:newsml_CSEfpjt:0-genmab-a-s-admittance-to-trading-and-official-listing-of-new-shares-due-to-employee-warrant-exercise/
0 · Reply
Fugazi_
Fugazi_ Dec. 1 at 2:53 PM
$GMAB does anyone know why thecalls went up 10x?
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 30 at 2:04 AM
The attached graph compares $NUVL analyst consensus revenue estimates to the same for $MRUS as of the date the acquisition was announced and versus the revenue forecast MRUS provided $GMAB when GMAB agreed to acquire MRUS for an enterprise value of roughly $7.3B. NUVL's market cap is roughly $8.4B per Yahoo Finance. With roughly $1B cash, NUVL's enterprise value is $7.4B. This is not investment advice. We're merely sharing an observation. Just to be clear, note analysts have higher revenue estimates for NUVL in the outer years. $XBI $IBB
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Nov. 25 at 2:47 PM
$GMAB RSI: 72.49, MACD: 0.2616 Vol: 0.90, MA20: 29.74, MA50: 30.33 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
smartkarma
smartkarma Nov. 21 at 7:14 PM
$GMAB | Genmab’s $8 Billion Bet: What The Merus Deal Could Unlock! "The Danish biotech giant is gearing up to acquire Merus N.V., a smaller Dutch peer, in a proposed $8 billion transaction announced on September 29, 2025." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/genmab-s-8-billion-bet-what-the-merus-deal-could-unlock
0 · Reply
AlxNT
AlxNT Nov. 21 at 12:34 PM
$HALO I discovered this stock because I'm a shareholder of $GMAB. It looks like a wonderful company. Unfortunately, I don't have cash anymore, but it's definitely on my watch-list until I sell another position.
0 · Reply
jrobbins64
jrobbins64 Nov. 19 at 3:24 PM
$GMAB Should be over $40 now!
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 18 at 4:41 PM
$GMAB $ABBV
0 · Reply